Fig. 2

Promotion of Anlotinib-regulated circHAS2 in CRC proliferation in vitro and in vivo. A The viabilities of SW620/vector, SW620/circHAS2 oe with the addition of vehicle control or anlotinib were detected by CCK-8 assays in SW620 cells. B Quantitative results and representative images of cell proliferation were conducted by colony formation assay with indicated treatment in SW620 cells. C Quantitative results and representative images of cell proliferation were evaluated by EdU incorporation with indicated treatment in SW620 cells (scale bar: 50 μm). D The percentage of cells in the G1, S, and G2 phases of the whole cell population was determined by flow cytometry with indicated treatment in SW620 cells. E Representative images of organoids in the vector- and circHAS2 overexpression-treated groups treated with the indicated concentrations of anlotinib (scale bar: 10 μm). F Dose–effect curves of organoids in the vector- and circHAS2 overexpression-treated groups treated with the indicated concentrations of anlotinib. G Images of subcutaneous tumors formed by SW620/vector, SW620/circHAS2 oe cells (n = 5). The mice were administered either a vehicle control or anlotinib (3 mg/kg, orally, every two days), respectively. H Tumor weights were analyzed at the endpoint. I Tumor volumes were measured every two days. J IHC scores of IHC staining (Ki-67 and CD31) assay of tumors of indicated treatment. Cell viability was determined by CCK-8 assay, employing two-way analysis of variance. Statistical differences in clone formation, EdU experiments, tumor weights, tumor volumes and IHC scores were assessed using two-sided Student’s t-test. Survival analysis was performed using the Log-rank method. Data are represented as mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, no significance